Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 1, 2012, Pages

  Ronden, Rianne A ^a   Houben, Alfons J H M ^a   Teerlink, Tom ^b   Bakker, Jaap A ^c   Bierau, Jörgen ^c   Stehouwer, Coen D A ^a   de Leeuw, Peter W ^a   Kroon, Abraham A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dimethylarginines; Hypertension; Renal function

Indexed keywords

6 N,N' DIMETHYLARGININE; N(G),N(G) DIMETHYLARGININE;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY ANGIOGRAPHY; KIDNEY BLOOD FLOW; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN RENAL BLOOD FLOW; PLASMA CLEARANCE; PRIORITY JOURNAL; RENAL PLASMA CLEARANCE;

EID: 84863320808     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00045.2012     Document Type: Article

References (55)

1. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23: 1455-1459, 2003.
2. G-dimethylarginine in renal insufficiency. Pflugers Arch 439: 524-531, 2000.
3. Andersson LG, Bratteby LE, Ekroth R, Wesslen O, Hallhagen S. Calculation of renal extraction during high diuresis and low renal plasma flow conditions. Clin Physiol 14: 79-85, 1994.
4. Gdimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 8: 1437-1442, 1997.
5. Bergamini S, Vandelli L, Bellei E, Rota C, Manfredini P, Tomasi A, Albertazzi A, Iannone A. Relationship of asymmetric dimethylarginine to haemodialysis hypotension. Nitric Oxide 11: 273-278, 2004.
6. Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, Reinecke H. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 17: 1128-1134, 2006.
7. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1842-1847, 1998.
8. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Boger SM. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of Sadenosylmethionine-dependent methyltransferases. Circ Res 87: 99-105, 2000.
9. Buijs MM, de Leeuw PW, Houben AJ, Kroon AA, Frolich M, Pijl H, Meinders AE. Renal contribution to increased clearance of exogenous growth hormone in obese hypertensive patients. J Clin Endocrinol Metab 90: 795-799, 2005.
10. Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, Vural A, Zoccali C. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 70: 781-787, 2006.
11. Carello KA, Whitesall SE, Lloyd MC, Billecke SS, D'Alecy LG. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 290: H209-H216, 2006.
12. de Leeuw PW, Birkenhager WH. Use of the xenon-133 washout technique in diagnosing renovascular disease in hypertension. Nephron 44, Suppl 1: 5-7, 1986.
13. G-dimethyl-L-arginine or asymmetric dimethylarginine and related pathway's metabolites in biological fluids by ultrahigh-performance liquid chromatography/ electrospray ionization-tandem mass spectrometry. Anal Chim Acta 677: 140-148, 2010.
14. Fleck C, Schweitzer F, Karge E, Busch M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta 336: 1-12, 2003.
15. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461, 2005.
16. Fogteloo AJ, Meinders AE, Pijl H, Kroon AA, Frolich M, De Leeuw PW. Renal clearance of endogenous leptin in hypertensive humans with or without renal artery stenosis. Am J Physiol Endocrinol Metab 281: E400-E404, 2001. 16a. Hollenberg NK, Mangel R, Fung HY. Assessment of intrarenal perfusion with radioxenon: a critical review of analytical factors and their implications in man. Semin Nucl Med 6: 193-216, 1976.
17. Hu X, Atzler D, Xu X, Zhang P, Guo H, Lu Z, Fassett J, Schwedhelm E, Boger RH, Bache RJ, Chen Y. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol 31: 1540-1546, 2011.
18. Kalousova M, Kielstein JT, Hodkova M, Zima T, Dusilova-Sulkova S, Martens-Lobenhoffer J, Bode-Boger SM. No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif 24: 439-444, 2006.
19. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13: 170-176, 2002.
20. Kielstein JT, Fliser D, Veldink H. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance? Semin Dial 22: 346-350, 2009.
21. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant 21: 2446-2451, 2006.
22. G-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch Biochem Biophys 300: 657-662, 1993.
23. Ladefoged J. Measurements of the renal blood flow in man with the 133 xenon wash-out technique. A description of the method. Scand J Clin Lab Invest 18: 299-315, 1966.
24. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343: 209-214, 1999.
25. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003.
26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009.
27. Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Del Olmo JA, Rodrigo JM, Serra MA. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 231: 70-75, 2006.
28. Luo Z, Teerlink T, Griendling K, Aslam S, Welch WJ, Wilcox CS. Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells. Hypertension 56: 498-504, 2010.
29. Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int 16: 251-270, 1979.
30. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11: 2449-2452, 1996.
31. Marescau B, Nagels G, Possemiers I, De Broe ME, Becaus I, Billiouw JM, Lornoy W, De Deyn PP. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 46: 1024-1031, 1997.
32. Martens-Lobenhoffer J, Bode-Boger SM. Chromatographic-mass spectrometric methods for the quantification of L-arginine and its methylated metabolites in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 851: 30-41, 2007.
33. Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, Fujimura T, Matsuoka H, Kimoto M, Kato S, Imaizumi T, Okuda S. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17: 2176-2183, 2006.
34. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99: 1141-1146, 1999.
35. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, ter Wee PM, van Guldener C. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 68: 2230-2236, 2005.
36. Nijveldt RJ, Siroen MP, Teerlink T, van Leeuwen PA. Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure? J Nutr 134: 2848S-2853S, 2004.
37. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 17: 1999-2002, 2002.
38. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65: 1009-1016, 2004.
39. Ogawa T, Kimoto M, Sasaoka K. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine: glyoxylate aminotransferase 2. J Biol Chem 265: 20938-20945, 1990.
40. Perticone F, Maio R, Tripepi G, Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 110: 821-825, 2004.
41. Rennenberg RJ, Schurgers LJ, Vermeer C, Scholte JB, Houben AJ, de Leeuw PW, Kroon AA. Renal handling of matrix Gla-protein in humans with moderate to severe hypertension. Hypertens Res 31: 1745-1751, 2008.
42. Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem 285: 5385-5391, 2010.
43. Siroen MP, van der Sijp JR, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PA. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 41: 559-565, 2005.
44. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27: 765-769, 2004.
45. Teerlink T. ADMA metabolism and clearance. Vasc Med 10, Suppl 1: S73-S81, 2005.
46. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res 60: 448-460, 2009.
47. Tran CT, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 68: 101-105, 2000.
48. Ueda S, Yamagishi S, Okuda S. New pathways to renal damage: role of ADMA in retarding renal disease progression. J Nephrol 23: 377-386, 2010.
49. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992.
50. Waterval WA, Scheijen JL, Ortmans-Ploemen MM, Habets-van der Poel CD, Bierau J. Quantitative UPLC-MS/MS analysis of underivatised amino acids in body fluids is a reliable tool for the diagnosis and follow-up of patients with inborn errors of metabolism. Clin Chim Acta 407: 36-42, 2009.
51. Wierema TK, Houben AJ, Kroon AA, Koster D, van der Zander K, van Engelshoven JM, de Leeuw PW. Nitric oxide dependence of renal blood flow in patients with renal artery stenosis. J Am Soc Nephrol 12: 1836-1843, 2001.
52. Wilcox CS. Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables. Hypertension 59: 375-381, 2012.
53. Yeung KK, De Gouyon Matignon C, Renwarin L, Tjon AFMR, Teerlink T, van Leeuwen PA, Musters RJ, Wisselink W, Tangelder GJ. Hypothermic renal perfusion during aortic surgery reduces the presence of lipocalin-2 and preserves renal extraction of dimethylarginines in rats. Am J Physiol Renal Physiol 301: F1231-F1241, 2011.
54. Zoccali C. Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J Am Soc Nephrol 17: S61-S63, 2006.
55. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117, 2001.